Delta’s Board of Directors Approves the Acquisition of ACT Genomics to Strengthen its Portfolio of Healthcare Solutions

TAIPEI, June 18, 2025 – Delta Electronics, Inc. (later referred to as “Delta”), a global leader in power management and smart green solutions, announced today the approval by its board of directors to acquire up to 177,142,221 ordinary shares(*) of ACT Genomics Holdings Company Limited (later referred to as “ACT Genomics”) for up to US$71.78 million. The transaction can only be completed if more than 90% of ACT Genomics’ stake in each class of ordinary shares is acquired. ACT Genomics provides next-generation sequencing (NGS), an advanced technology applied in oncology for early cancer detection, molecular diagnostics, treatment selection, and post-treatment monitoring, supporting a comprehensive approach to precision cancer care. Delta expects to enhance its capabilities in the healthcare sector through this transaction.

Ping Cheng, Delta’s Chairman and CEO, said, “Population ageing and the rising incidence of cancer worldwide are amplifying the demand for advanced healthcare. NGS technology is promising due to its ability to detect multiple disease-related gene variants, which enables precision medicine to deliver tailored treatment to patients. ACT Genomics has established a leading position in the NGS field in Asia, and we believe that its innovative technology can complement Delta’s resources and healthcare solutions portfolio, ultimately enhancing our position in the biomedical field.”

Hua Chien Chen, ACT Genomics’ CEO, said, “ACT Genomics strives to improve the quality of life of every cancer patient through advanced healthcare solutions. Our remarkable team of healthcare professionals in the fields of oncology, cancer genomics, and bioinformatics, are driving the adoption of precision diagnostics and treatment of cancerous diseases. Delta’s global presence and capabilities can help ACT Genomics not only extend our reach in key target markets, but also deepen our exposure into existing markets.”

Founded in 2014, ACT Genomics is a leading provider of NGS technology in Asia with operations in key markets, such as Taiwan, Singapore, Japan, Thailand, and Hong Kong. Its internationally-certified genomics clinical testing lab leverages NGS technology and the company’s own know-how to analyze over 440 cancer-associated genes across pan-cancer types, while also being the only lab outside the U.S. to achieve the clearance by the U.S. Food & Drug Administration (FDA) for its NGS comprehensive tumor profiling panel offering. These unique capabilities allow ACT Genomics to provide advanced genomic treatments and personalized medicine services to the cancer patients of healthcare providers, including over 80 partners in Taiwan, such as hospitals and clinics, pharmaceutical companies, insurance companies, and academic research institutions.

Notes:
(*) The price at which shares are acquired may differ based on the stakeholder involved. The closing of the transaction is subject to satisfaction of certain closing conditions, such as regulatory approvals, and more than 90% of ACT Genomics’ stake in each class of ordinary shares being acquired.